Recent developments of acupuncture in Australia and the way forward.

Almost one in ten Australians has received acupuncture treatment by acupuncturists and/or medical doctors in private clinics. The majority of Australian health insurance funds offer rebates for acupuncture. Statutory regulations for acupuncture have been implemented in the State of Victoria, Australia. Six acupuncture degree courses have been approved by the Chinese Medicine Registration Board of Victoria and/or accredited by the Australian Acupuncture and Chinese Medicine Association. Furthermore, a number of clinical trials of acupuncture on allergic rhinitis, pain and women's health were carried out in Australia. Recent developments of acupuncture in Australia indicate that through adequate and appropriate evaluation, acupuncture begins to integrate into mainstream health care in Australia.

Inhibition of release of inflammatory mediators in rat peritoneal mast cells and murine macrophages by a Chinese herbal medicine formula (RCM-102).

RCM-102 is a Chinese herbal medicine formulation derived from a formula which was shown to be effective in treating seasonal allergic rhinitis (SAR) in a randomized placebo-controlled trial. The aim of this study was to investigate the in vitro effect of RCM-102 on the formation of inflammatory mediators, histamine, prostaglandin and nitric oxide, which are known to be involved in the pathophysiology of SAR. The effect of RCM-102 on histamine release was tested in compound 48/80-stimulated rat peritoneal mast cells. The effects of RCM-102 on the release of NO and prostaglandins (PGE(2)) and the expression of inducible NO synthase (iNOS) and COX-2 were studied in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. In rat peritoneal mast cells, RCM-102 significantly reduced the compound 48/80-induced histamine release. It also significantly reduced NO and PGE(2) production as well as the expression of COX-2 and iNOS in RAW 264.7 cells. These findings indicate that RCM-102 inhibits the formation of several allergic/inflammatory mediators and thus may be used for treating related conditions such as SAR. The actions of RCM-102 are likely to be contributed by the synergistic actions of individual herbal ingredients.

A population survey on the use of 24 common medicinal herbs in Australia.

BACKGROUND: Herbal medicine use is common in Australia but little is known about the use of individual herbs. METHODS: A cross-sectional population survey conducted in 2007 with a sample of 2526, in the Australian state of Victoria. RESULTS: Almost a quarter (22.6%, 95% confidence interval (CI): 20.9-24.2%) of survey participants had used at least one medicinal herb in the preceding 12 months. Aloe vera, garlic and green tea were the most popular, each used by about 10% of participants. Health enhancement was the most common reason for herbal medicine use (69.6% of users) but relatively high proportions of users sought relief of specific medical conditions. Over 90% considered their herbal medicine to be very or somewhat helpful. Less than half (46.6%) the users were aware that there were potential risks associated with herbal medicine. Relatively high proportions of female users had taken herbal medicine whilst pregnant (14.4%) and/or whilst breast feeding (10.0%). Over half (50.9%) of herbal medicine users had also used Western medicine for the same medical condition in the 12-month period. Almost the same proportion (49.9%) had used both forms of medication on the same day. In deciding whether or not to use herbal medicine, the vast majority of survey participants indicated that they would accept the advice of their medical practitioner. CONCLUSIONS: In addition to health enhancement, specific herbs are commonly used to treat a range of medical conditions, without clear evidence of efficacy. Concurrent use of herbal and conventional medicine is relatively common and the majority of herbal medicine users are not aware of potential adverse effects. It appears that medical practitioners could exert significant influence on their patients' decisions about herbal medicine use.

Inhibition of inducible nitric oxide production and iNOS protein expression in lipopolysaccharide-stimulated rat aorta and Raw 264.7 macrophages by ethanol extract of a Chinese herbal medicine formula (RCM-101) for allergic rhinitis.

AIM OF THE STUDY: A Chinese herbal formula (RCM-101) has shown to be effective in reducing symptoms of seasonal allergic rhinitis (SAR) in a randomised, placebo-controlled clinical trial. The aim of this study is to investigate the effects of RCM-101 on the actions and synthesis of nitric oxide (NO). l-Arginine-induced endothelium-independent relaxations were studied in rat isolated aorta which was pre-treated with lipopolysaccharide (LPS). MATERIALS AND METHODS: NO production and inducible nitric oxide synthase (iNOS) protein expression were studied in LPS and interferon gamma-stimulated murine macrophages (Raw 264.7), measured by NO sensors and Western blotting. RESULTS: In rat aortic preparations, RCM-101 significantly inhibited endothelium-independent relaxations to l-arginine, but not affected those to sodium nitroprusside (SNP). In Raw 264.7 cells, RCM-101 and some of its individual ingredients (e.g., Radix glycyrrhizae, Radix bupleuri, Radix saposhnikoviae and Atractylodis rhizome macrocephalae) significantly inhibited the NO production and iNOS protein expression. CONCLUSIONS: The findings indicate that RCM-101 may inhibit inducible NO production by suppressing iNOS. In addition, its inhibitory action of iNOS is likely to be mediated by several key herbal ingredients.

Inhibition of release of vasoactive and inflammatory mediators in airway and vascular tissues and macrophages by a chinese herbal medicine formula for allergic rhinitis.

Herbal therapies are being used increasingly for the treatment of allergic rhinitis. The aim of this study was to investigate the possible pharmacological actions and cellular targets of a Chinese herbal formula (RCM-101), which was previously shown to be effective in reducing seasonal allergic rhinitis symptoms in a randomized, placebo-controlled clinical trial. Rat and guinea pig isolated tissues (trachea and aorta) were used to study the effects of RCM-101 on responses to various mediators. Production of leukotriene B(4) in porcine neutrophils and of prostaglandin E(2) and nitric oxide (NO) in Raw 264.7 cells were also measured. In rat and guinea pig tracheal preparations, RCM-101 inhibited contractile responses to compound 48/80 but not those to histamine (guinea pig preparations) or serotonin (rat preparations). Contractile responses of guinea pig tracheal preparations to carbachol and leukotriene C(4,) and relaxant responses to substance P and prostaglandin E(2) were not affected by RCM-101. In rat aortic preparations, precontracted with phenylephrine, endothelium-dependent relaxant responses to acetylcholine and endothelium-independent relaxant responses to sodium nitroprusside were not affected by RCM-101. However, RCM-101 inhibited relaxations to l-arginine in endothelium-denuded rat aortic preparations, which had been pre-incubated with lipopolysaccharide. RCM-101 did not affect leukotriene B(4) formation in isolated porcine neutrophils, induced by the calcium ionophore A23187; however, it inhibited prostaglandin E(2) and NO production in lipopolysaccharide-stimulated murine macrophages (Raw 264.7 cells).The findings indicate that RCM-101 may have multiple inhibitory actions on the release and/or synthesis of inflammatory mediators involved in allergic rhinitis.

Comparison of Chinese medicine education and training in China and Australia.

The similarities and differences between Chinese medicine (CM) education in China and Australia are considered in a detailed comparison of the five-year undergraduate programmes offered by the Beijing University of CM (BUCM), China and RMIT University (RMIT), Australia. BUCM is a specialist CM institution whereas RMIT is a technological university providing training in a wide range of professional areas. Both institutions are considered to be leading tertiary institutions within their respective countries. A brief account of the historical development of CM education in China and Australia is provided. We have compared the curricula and structure of the programmes and how they each address the development of essential graduate capabilities for competent and safe clinical CM practice. We have also considered the quality assurance processes and the requirements of external regulatory authorities. The curricula and educational objectives of the 2 programmes are broadly similar. Both institutions have established rigorous processes for managing teaching quality and ensuring appropriate graduates to promote evidence-based CM practice. However, there are differences relating to the healthcare systems of China and Australia and to the availability of teaching resources and clinical training facilities such as classical CM texts and CM hospitals. These differences present major challenges for the internationalisation of CM education. The findings of this study may facilitate the process of CM curriculum development in a global context.